



September 15, 2023

Company Name:	GNI Group Ltd.
Representative:	Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth)
Contact Person:	Chief Strategy Officer Toshiya Kitagawa (TEL. 03-6214-3600)

### On Kaisha Shikihou Article

In Kaisha Shikihou published today (2024 4<sup>th</sup> Autumn Edition by Toyo Keizai Inc.), it is stated that "In the fiscal year ending December 2024, the operating profits will drop due to the lack of one-time payment despite strong pharmaceutical performance." However, the company has not announced any forecast figures or given any answer that our operating profits will decrease. Investors should be careful when making investment decisions.

Our company has not made any numerical announcements, but as we answered in the Q&A published on August 25, 2023, we believe that we will be able to grow steadily in the next fiscal year.

---

#### About GNI Group Ltd.:

The Company is a holding company of global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below:

<https://www.gnipharma.com/>

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. ("the Company"). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.